Abstract: A graphene oxide (GO)-silver nanoparticles (AgNPs)-Eu3+ fluorescent probe, a paper-based sensor, and a preparation method and use thereof are provided. The paper-based sensor is developed based on a GO-AgNPs-Eu3+ fluorescent probe-loaded polyvinylidene fluoride (PVDF) microporous membrane, which is further combined with a smartphone. The GO-AgNPs-Eu3+ fluorescent probe shows high selectivity for 2,6-dipicolinic acid (DPA), strong anti-interference ability, and low limit of detection (LOD) for the DPA and spores. The paper-based sensor realizes quantitative detection of the DPA and the spores through red, green, and blue (RGB) changes of the smartphone, and detection results are verified by an actual amount of the spores in milk and water. The rapid detection of foodborne spores is achieved through a dual-function platform based on fluorescence of the GO-AgNPs-Eu3+ fluorescent probe and the paper-based sensor.

Abstract: Provided are a gas separation membrane, and a preparation method therefor and the use thereof. The gas separation membrane comprises 60-100 mol % of a monomeric unit derived from ?,?,?-trifluorostyrene, and has an intrinsic viscosity of 0.5-5.0 dL/g and a tensile strength of at least 50 MPa. According to the GB/T 1038-2000 test method test, the permeability coefficient of hydrogen is at least 100 barrer.

Abstract: A treatment for reducing glucose bioaccessibility can include providing a superabsorbent material that includes a porous network structure formed from a mixture of a plurality of water soluble polysaccharides that are not chemically crosslinked together. The superabsorbent material can be administered to a subject in an effective amount to reduce glucose bioaccessibility in the subject. In some aspects, the treatment for reducing glucose bioaccessibility with the superabsorbent material retains a substantially unaltered fatty acid bioaccessibility and/or retains a substantially unaltered protein bioaccessibility.

Abstract: The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

Abstract: The disclosure relates to the technical filed of organic synthesis, in particular to a method for preparing veratrole. In the disclosure, veratrole is prepared by using lithium hydroxide instead of sodium hydroxide, catechol as raw material, and dimethyl sulfate as methylating agent. Comparing with the existing method of adding sodium hydroxide solution, the method according to the disclosure allows reduced reaction temperature, shortened reaction time, and thereby improves the stability and safety of the reaction and the product yield. The experimental data of the examples in the disclosure shows a veratrole yield up to 95%. Furthermore, the preparation method according to the disclosure does not need to be carried out under a reflux condition, the operation of which is simpler, thereby further improving the safety and stability of the reaction.

Abstract: Disclosed are novel compounds of Formula I that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

Abstract: The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

Abstract: The present disclosure relates to a technical field of iron and steel material, in particular to an oriented electrical steel with high magnetic induction and annealing method thereof. Impeccable secondary recrystallization and single Goss texture are formed by controlling the heating rate and the atmosphere of the annealing treatment, confirming beginning and ending temperature in accordance with different heating rate. The orientation density of the Goss texture is more than 145. The magnetic induction intensity B8 is increased by 1-3% compared with products of same grade.

Abstract: The present disclosure provides a method and system for quantifying a degree of blending of virgin and aged asphalt in HRAM. The method includes the following steps: first, constructing a relational equation between the microscale modulus of recycled asphalt in a fully blended state and the content of the aged asphalt; measuring the microscale modulus of the recycled asphalt, the microscale modulus of the aged asphalt, the microscale modulus of the virgin asphalt, and the content of the aged asphalt in the HRAM in situ; inputting the dates above into the relational equation to obtain the microscale modulus of the recycled asphalt in the fully blended state; and based on the microscale modulus of the recycled asphalt measured in situ and the microscale modulus of the recycled asphalt in the fully blended state, obtaining the degree of blending of the virgin and aged asphalt in the HRAM.

Abstract: Provided are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, tautomers, isotopically labeled derivatives, polymorphs, and prodrugs thereof, wherein X1-X4, RX, RC, RB, n, and Ring A are as defined herein. The compounds may be aryl hydrocarbon receptor agonists or partial aryl hydrocarbon receptor agonists. Also provided are pharmaceutical compositions comprising a compound of Formula (I) and methods of using such compounds for treating diseases and conditions related to the activity of an aryl hydrocarbon receptor, such as, for example, inflammatory diseases, autoimmune diseases, metabolic disorders, and proliferative diseases.

Abstract: Disclosed are an accelerated test data analysis method and apparatus based on a grey forecast model, a device.

Abstract: A performance degradation-based product reliability weak link evaluation method includes: acquiring a performance degradation parameter of each component of a to-be-evaluated product corresponding to each test time point; evaluating the performance degradation parameter of each component corresponding to each test time point through a fault time evaluation model, to obtain a pre-fault operating duration of each component; evaluating the pre-fault operating duration of each component through a confidence-based unreliability evaluation method, to obtain an unreliability evaluation result of each component; generating at least one component service life distribution model corresponding to each component according to the unreliability evaluation result, and selecting a corresponding target component service life distribution model; and evaluating mean time between failures corresponding to each component according to the target component service life distribution model, and selecting a reliability weak link of th

Abstract: The present disclosure discloses a method and apparatus for estimating product lifetime based on a multi-stress accelerated test, and a device. This method can be applied in the field of data processing technologies, specifically including: determining, in response to a lifetime estimation request for a target product, a target characteristic lifetime of the target product based on a target stress condition for the target product and correspondence relationships between candidate stress conditions and candidate characteristic lifetimes; and determining, based on an optimal lifetime model for the type to which the target product belongs and the target characteristic lifetime, a target average life of the target product.

Abstract: The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

Abstract: The present disclosure relates to a method and an apparatus for processing accelerated test data based on multiple performance degradation, and a device.

Abstract: The present disclosure relates to a method and an apparatus for processing accelerated test data based on multiple performance degradation, and a device.

Abstract: The present disclosure relates to a method and an apparatus for reliability evaluation based on multiple performance degradation, a computer device, a storage medium, and a computer program product. The method includes: for each of the multiple performances of a target product, obtaining a plurality of candidate functions that the performance possibly follows, determining a target function that satisfies a preset selection condition from the plurality of candidate functions, and determining a reliability function corresponding to the performance based on the target function; determining coupling relation information between the multiple performances of the target product, and obtaining redundancy information of the multiple performances of the target product; and performing a reliability evaluation on the target product based on the coupling relation information, the redundancy information, and the reliability function of each performance.

Abstract: The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

Abstract: A method for processing accelerated degradation test data based on Wiener process includes obtaining accelerated degradation test data of a to-be-tested product, selecting a target time conversion model from a predefined set of time conversion models based on the accelerated degradation test data, constructing a nonlinear Wiener degradation process based on the target time conversion model, determining a product reliability function of the to-be-tested product, and testing the reliabilities of the to-be-tested product based on the product reliability function to obtain product reliability test results of the to-be-tested products.

Abstract: Disclosed are novel compounds of Formula I that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.